Silence Therapeutics Secures $2M Milestone Payment From Hansoh In Groundbreaking Deal

Silence Therapeutics plc, a biotechnology company dedicated to revolutionizing healthcare by "silencing" diseases with precision-engineered medicines, is set to receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited. This payment comes as a result of reaching the second undisclosed milestone related to the first target in their ongoing collaboration.

 Craig Tooman, CEO and President of  Silence, “This represents an important milestone in our efforts to advance this program into the clinic with Hansoh. This is an exciting time for Silence and our mRNAi GOLD platform as we continue to advance and expand our pipeline targeting a wide range of genetic diseases.”

 In October 2021, Silence and Hansoh began a partnership to create siRNAs (short interfering RNAs) using Silence's unique mRNAi GOLD platform, focusing on three unnamed targets. According to the agreement, Silence holds exclusive rights to the first two targets globally, except for the China region. Hansoh retains an exclusive option to license the rights to these two targets in Greater China, including Hong Kong, Macau, and Taiwan, as well as global rights to the third target. The announcement today marks the fourth research milestone payment attained within this collaboration.